VKVirunya Komenkul

Virunya Komenkul

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Virunya Komenkul has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Precision Dosing of Tacrolimus in Liver Transplantation: Integrating Donor‐Recipient CYP3A5 Pharmacogenomics and Drug Interactions

    by Virunya Komenkul, Prawat Chantharit, Piyawat Komolmit, Bunthoon Nonthasoot, Athaya Vorasittha, Anapat Sanpavat, Sirinporn Suksawatamnuay, Chandramouli Radhakrishnan, Thitima Wattanavijitkul

    Tacrolimus dosing in liver transplantation is complicated by a narrow therapeutic index and high CYP3A5 genetic variability. While saturable Michaelis–Menten kinetics can explain nonlinearities, identifying saturable parameters from routine clinical data remains challenging. This study aimed to determine the optimal structural model and develop a precision dosing algorithm. A population pharmacokinetic analysis was conducted in 114 patients, yielding 1989 observations. CYP3A5 genotypes were determined for both recipients and donors. Using Phoenix NLME, we rigorously compared linear versus Michaelis–Menten elimination structures. Stepwise covariate modeling was conducted to quantify the impact of genetic, physiological, and pharmacological factors, followed by Monte Carlo simulations to optimize dosing. A conventional two‐compartment model adequately described the data without requiring a Michaelis–Menten structure. The combined CYP3A5 genotype exhibited a distinct stepwise reduction in apparent clearance from the homozygous expressor to the non‐expressor group. Fluconazole emerged as a major inhibitor, reducing clearance by 33%, whereas prednisolone showed modest induction. Hemoglobin displayed a significant inverse relationship with clearance. Crucially, incorporating the daily dose as a covariate on clearance effectively captured the apparent nonlinear disposition. Simulations confirmed that fluconazole‐treated patients require substantially lower doses (1.5–3.0 mg every 12 h) compared with fluconazole‐free patients (2.5–7.0 mg every 12 h). A dose‐dependent two‐compartment model offers a basis for model‐informed dose selection, addressing reported nonlinearities through physiological covariates. We provide a model‐informed dosing algorithm that accounts for combined recipient/donor genetics and drug interactions, which may improve target attainment in liver transplant populations.

  • External validation of population pharmacokinetic models of tacrolimus in Thai adult liver transplant recipients

    by Virunya Komenkul, Waroonrat Sukarnjanaset, Piyawat Komolmit, Thitima Wattanavijitkul

    Objective Several population pharmacokinetic models of tacrolimus in liver transplant patients were built, and their predictability was evaluated in their settings. However, the extrapolation in the prediction was unclear. This study aimed to evaluate the predictive performance of published tacrolimus models in adult liver transplant recipients using data from the Thai population as an external dataset. Methods The selected published models were systematically searched and evaluated for their quality. The external dataset of patients who underwent the first liver transplant and received immediate-release tacrolimus was used to assess the predictive performance of each selected model. Trough concentrations between 3 and 6 months were retrospectively collected to evaluate the predictability of each model using prediction-based diagnostics, simulation-based diagnostics, and Bayesian forecasting. Results Sixty-seven patients with 360 trough concentrations and eight selected published models were included in this study. None of the models met the predictive precision criteria in prediction-based diagnostics. Meanwhile, four published population pharmacokinetic models showed a normal distribution in NPDE testing. Regarding Bayesian forecasting, all models improved their forecasts with at least one prior information data point. Conclusion Bayesian forecasting is more accurate and precise than other testing methods for predicting drug concentrations. However, none of the evaluated models provides satisfactory predictive performance for generalization to Thai liver transplant patients. This underscores the need for future research to develop population PK models tailored to the Thai population. Such efforts should consider the inclusion of nonlinear pharmacokinetics and region-specific factors, including genetic variability, to improve model accuracy and applicability.


  • Population pharmacokinetic models of tacrolimus in paediatric solid organ transplant recipients: A systematic review

    by Kanyaporn Khamlek, Virunya Komenkul, Tatta Sriboonruang, Thitima Wattanavijitkul

    Aims: This study aimed to provide up‐to‐date information on paediatric population pharmacokinetic models of tacrolimus and to identify factors influencing tacrolimus pharmacokinetic variability.Methods: Systematic searches in the Web of Science, PubMed, Scopus, Science Direct, Cochrane, EMBASE databases and reference lists of articles were conducted from inception to March 2023. All population pharmacokinetic studies of tacrolimus using nonlinear mixed‐effect modelling in paediatric solid organ transplant patients were included.Results: Of the 21 studies reviewed, 62% developed from liver transplant recipients and 33% from kidney transplant recipients. Most studies used a 1‐compartment model to describe tacrolimus pharmacokinetics. Body weight was a significant predictor for tacrolimus volume of distribution (Vd/F). The estimated Vd/F for 1‐compartment models ranged from 20 to 1890 L, whereas the peripheral volume of distribution (Vp/F) for 2‐compartment models was between 290 and 1520 L. Body weight, days post‐transplant, CYP3A5 genotype or haematocrit were frequently reported as significant predictors of tacrolimus clearance. The estimated apparent clearance values range between 0.12 and 2.18 L/h/kg, with inter‐individual variability from 13.5 to 110.0%. Only 29% of the studies assessed the generalizability of the models with external validation.Conclusion: This review highlights the potential factors, modelling approaches and validation methods that impact tacrolimus pharmacokinetics in a paediatric population. The clinician could predict tacrolimus clearance based on body weight, CYP3A5 genotype, days post‐transplant or haematocrit. Further research is required to determine the relationship between pharmacogenetics and tacrolimus pharmacodynamics in paediatric patients and confirm the applicability of nonlinear kinetics in this population.